CRISPRO · KNOWLEDGE BASE
CrisPRO Blog
Insights, news, and research at the intersection of AI and oncology — organized by series where it matters.
Series · 3 parts
Platinum Window Hypothesis
Read in order — each part builds on the last.
- Part 2Apr 9, 2026
Part 2: Who is the system failing most, and why?
We built a computational engine and pointed it at 427 real ovarian cancer patients. We asked one question: who is the system failing most, and why?
Read part 2 - Part 3Apr 9, 2026
Part 3: The Clock We Didn't Know Was Running
Two trials failed last year. Not because the drugs didn't work. Because nobody knew what time it was.
Read part 3 - Part 4Apr 9, 2026
Part 4: 2,500 Patients Just Told Us The Same Thing
We took two genes — FAP and CXCL10 — and asked a simple question in each cohort: do patients with FAP below their cohort average and CXCL10 above their cohort average live longer than everyone else?
Read part 4
Featured Article
Lung Cancer Brain Metastasis. Here's What We Found — and Why It Matters for a Cure.
Approximately 20–40% of non-small cell lung cancer (NSCLC) patients develop brain metastases — tumors that have broken away from the primary site, crossed the blood-brain barrier, and colonized the most protected organ in the human body. Once that happens, median survival drops to months.
Read Full StoryAlso on the blog
May 20, 2026
EscapeMap — We Built a Cancer Resistance Engine From Public Data Nobody Was Using
A research series on building AI-driven therapeutic intelligence from the graveyard of failed clinical trials.
May 08, 2026
Building Brain Metastasis Framework Studying Glioblastoma's (GBM) Trial Failures
Every GBM trial failure carries a failure signature — a specific combination of target validity, delivery architecture, patient selection, and resistance mechanism. The question for each trial is not "did it fail?" but "which failure mode applies, and does that mode exist in the BrM context?"